miR-145 inhibits invasion and metastasis by directly targeting Smad3 in nasopharyngeal cancer

Tumor Biology

Volumn 36, Issue 6, 2015, Pages 4123-4131

  Huang, Haiping ^a   Sun, Peng ^a   Lei, Zhe ^b,c   Li, Manyi ^a   Wang, Yihong ^a   Zhang, Hong Tao ^b,c   Liu, Jisheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c Suzhou Key Laboratory for Molecular Cancer Genetics   (China)

Author keywords

Invasion; Metastasis; miR 145; Nasopharyngeal cancer; Smad3

Indexed keywords

MICRORNA 145; SMAD3 PROTEIN; MICRORNA; MIRN145 MICRORNA, HUMAN; SMAD3 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS INHIBITION; NASOPHARYNX CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; BIOSYNTHESIS; CELL MOTION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; NASOPHARYNX TUMOR; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; SMAD3 PROTEIN;

EID: 84938989777     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3046-6     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.
2. McDermott AL, Dutt SN, Watkinson JC. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci. 2001;26(2):82–92.
3. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80(3):661–8. doi:10.1016/j.ijrobp.2010.03.024.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
5. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–31. doi:10.1038/nrg1379.
6. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science (New York, NY). 2005;309(5740):1519–24. doi:10.1126/science.1111444.
7. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13(6):633–41. doi:10.1016/s1470-2045(12)70102-x.
8. Liu N, Tang LL, Sun Y, Cui RX, Wang HY, Huang BJ, et al. MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma. Cancer Lett. 2013;329(2):181–8. doi:10.1016/j.canlet.2012.10.032.
9. Feng Y, Zhu J, Ou C, Deng Z, Chen M, Huang W, et al. MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1. Br J Cancer. 2014;110(9):2300–9. doi:10.1038/bjc.2014.122.
10. Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A, et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res CR. 2010;29:151. doi:10.1186/1756-9966-29-151.
11. Hart M, Wach S, Nolte E, Szczyrba J, Menon R, Taubert H, et al. The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer. FEBS J. 2013;280(9):2105–16. doi:10.1111/febs.12236.
12. Zhu X, Li Y, Xie C, Yin X, Liu Y, Cao Y, et al. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. J Int Cancer. 2014;135(6):1286–96. doi:10.1002/ijc.28774.
13. Peng W, Hu J, Zhu XD, Liu X, Wang CC, Li WH, et al. Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line. Tumour Biol Int Soc Oncodevelopmental Biol Med. 2014;35(4):2983–8. doi:10.1007/s13277-013-1383-x.
14. Chen H, Chen G, Chen Y, Liao W, Liu C, Chang K, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 2009;100(6):1002–11.
15. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, et al. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol. 2009;11(8):943–50. doi:10.1038/ncb1905.
16. Xue J, Lin X, Chiu WT, Chen YH, Yu G, Liu M, et al. Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-beta-dependent cancer metastasis. J Clin Invest. 2014;124(2):564–79. doi:10.1172/jci71104.
17. Xiao J, Xiang Q, Xiao YC, Su ZJ, Huang ZF, Zhang QH, et al. The effect of transforming growth factor-beta1 on nasopharyngeal carcinoma cells: insensitive to cell growth but functional to TGF-beta/Smad pathway. J Exp Clin Cancer Res CR. 2010;29:35. doi:10.1186/1756-9966-29-35.
18. Wu ZB, Cai L, Lin SJ, Lu JL, Yao Y, Zhou LF. The miR-92b functions as a potential oncogene by targeting on Smad3 in glioblastomas. Brain Res. 2013;1529:16–25. doi:10.1016/j.brainres.2013.07.031.
19. Han SU, Kim HT, Seong DH, Kim YS, Park YS, Bang YJ, et al. Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene. 2004;23(7):1333–41. doi:10.1038/sj.onc.1207259.
20. Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK. Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res. 2003;63(13):3783–90.
21. Yang Y, Liu L, Cai J, Wu J, Guan H, Zhu X, et al. Targeting Smad2 and Smad3 by miR-136 suppresses metastasis-associated traits of lung adenocarcinoma cells. Oncol Res. 2013;21(6):345–52. doi:10.3727/096504014x14024160459285.
22. Thakur N, Gudey SK, Marcusson A, Fu JY, Bergh A, Heldin CH et al. TGFβ-induced invasion of prostate cancer cells is promoted by c-Jun-dependent transcriptional activation of Snail1. Cell cycle (Georgetown, Tex). 2014;13(15)
23. Yamazaki K, Masugi Y, Effendi K, Tsujikawa H, Hiraoka N, Kitago M, et al. Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma. Lab Investig J Tech Methods Pathol. 2014;94(6):683–91. doi:10.1038/labinvest.2014.53.
24. Rani SB, Rathod SS, Karthik S, Kaur N, Muzumdar D, Shiras AS. MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells. Neuro-Oncology. 2013;15(10):1302–16. doi:10.1093/neuonc/not090.
25. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature. 2009;460(7254):529–33. doi:10.1038/nature08199.
26. Shen YA, Lin CH, Chi WH, Wang CY, Hsieh YT, Wei YH, et al. Resveratrol impedes the stemness, epithelial-mesenchymal transition, and metabolic reprogramming of cancer stem cells in nasopharyngeal carcinoma through p53 activation. Evid-Based Complement Alternat Med eCAM. 2013;2013:590393. doi:10.1155/2013/590393.
27. Xhemalce B, Robson SC, Kouzarides T. Human RNA methyltransferase BCDIN3D regulates microRNA processing. Cell. 2012;151(2):278–88. doi:10.1016/j.cell.2012.08.041.
28. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 2008;454(7200):56–61. doi:10.1038/nature07086.